A man like a long-lived organism has excellent antitumor defense . Year after year, our immune system eliminates, without our knowledge, the tumors arising in our body. Only when she has bad luck and the tumor "does not catch" we will get cancer. Therefore, cancer can be considered as an immune failure.
The thing is even clearer when we realize that children with congenital immune deficiency (eg the famous "bubble baby") dying for cancer at an early age, even when doctors, with the help of a bubble and antibiotics, will be able to protect them from a fatal infection to which Would normally die.
It is therefore understandable that immunostimulatory adapogens have a chance to influence the course of the cancer.
And thus assign work to the immune system that normally destroys malignant neoplasms in our body both on the running belt. If any of the emerging cancer can escape, we may even die of cancer. This is the principle of tumor risk after irradiation.
How immunotherapy works
These methods fail in large metastases. In these cases, so-called biological treatment (bio-therapy) now exists, more correctly immunological treatment.
In chemotherapy, sometimes healthy cells can be partially protected by targeted perfusion of affected organs (since the 1950s) or bone marrow autotransplantation.
Immunotherapy for cancer is nothing new. There has long been an effort to create anticancer vaccines. Here, however, is the problem that the patient's own immune system is usually heavily damaged by cytostatic therapy. In today's immunotherapy, therefore, anti-cancer cells are artificially engineered and administered intragain to the patient. But this is not a miraculous method. The physician actually imitates the immune system of the patient and faces a challenge in which the natural immunity has failed once.
I consider the effort to combine antibodies with α-radioisotopes, which then locally irradiate small tumorous deposits (targeted alpha therapy). Targeted alpha therapy was devoted, for example, to No. 3 of Current Radiopharmaceuticals from September 2008 , from specific publications such as Tolmachev2007rth (lutetium 177 + HER2 anti- breast cancer antibodies) and Liepe2009a2a (Alpharadin, Prostate Cancer Radiation 223). Research activity in this field is progressing intensively, see Gudkov2016trt for a review.